Thyrotoxic periodic paralysis: clinical and molecular aspects

Area of Science:

• Endocrinology
• Genetics
• Neurology

Background:

• Thyrotoxic periodic paralysis (TPP) is a rare but serious complication of hyperthyroidism.
• It typically affects young males, often of East Asian descent, but is increasingly seen in other populations.
• TPP presents as acute episodes of muscle weakness or paralysis, often triggered by meals, exercise, or alcohol, with spontaneous recovery within 72 hours.

Purpose of the Study:

• To review the pathophysiology, clinical presentation, diagnosis, and management of thyrotoxic periodic paralysis.
• To highlight the interplay of genetic predisposition, thyrotoxicosis, and environmental factors in TPP.
• To discuss diagnostic challenges and therapeutic strategies for TPP.

Main Methods:

• Literature review of TPP, focusing on recent genetic findings and established clinical knowledge.
• Analysis of the underlying mechanisms, including ion channel function and hormonal influences.
• Synthesis of diagnostic criteria and treatment guidelines.

Main Results:

• TPP is characterized by hypokalemia due to potassium shifting into cells, driven by increased Na+/K+-ATPase activity.
• Mutations in the KCNJ18 gene, affecting the Kir2.6 potassium channel, are found in a subset of TPP patients.
• Diagnostic support includes hypokalemia, low urinary potassium, hypophosphatemia, and ECG abnormalities when thyroid tests are unavailable.

Conclusions:

• The pathophysiology of TPP is multifactorial, involving genetic susceptibility, hyperthyroidism, and environmental triggers.
• Prompt diagnosis and management, including cautious potassium supplementation or propranolol, are crucial.
• Definitive treatment requires addressing the underlying hyperthyroidism, though underlying mechanisms require further research.